Breaking News

NanoBio, Merck Enter Adjuvant Technology Pact

By Kristin Brooks | March 26, 2014

Will use NanoStat platform for RSV and flu vaccine development

NanoBio Corp. has signed a licensing agreement with a subsidiary of Merck for the use of its nanoemulsion (NE) adjuvant technology for vaccine development.
Merck will have exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal flu and/or universal seasonal flu vaccine. NanoBio will receive an upfront payment and is eligible to receive development and regulatory milestones, as well as royalties on sales of any Merck RSV or flu vaccines that use the NE adjuvant technology.
The NanoStat technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types, which, according to the company, is effective when administered via intranasal, intramuscular or subcutaneous vaccination.
"We've collaborated with Merck on research in RSV since 2011 and are very pleased to broaden our relationship with this license agreement covering vaccine candidates for two respiratory diseases," said David Peralta, chief executive officer of NanoBio. "Merck's demonstrated leadership in developing and marketing vaccines makes them an ideal partner for NanoBio."

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent